Hyperprogressive disease in patients with unresectable hepatocellular carcinoma receiving atezolizumab plus bevacizumab therapy (vol 52, pg 298, 2022)

被引：0
|
作者：
Maesaka, K.
Sakamori, R.
Yamada, R.
Tahata, Y.
Imai, Y.
Ohkawa, K.
机构：
来源：
HEPATOLOGY RESEARCH | 2022年 / 52卷 / 07期
关键词：
D O I：
10.1111/hepr.13775
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：659 / 659
页数：1
相关论文
共 50 条
  • [1] Hyperprogressive disease in patients with unresectable hepatocellular carcinoma receiving atezolizumab plus bevacizumab therapy
    Maesaka, Kazuki
    Sakamori, Ryotaro
    Yamada, Ryoko
    Tahata, Yuki
    Imai, Yasuharu
    Ohkawa, Kazuyoshi
    Miyazaki, Masanori
    Mita, Eiji
    Ito, Toshifumi
    Hagiwara, Hideki
    Yakushijin, Takayuki
    Kodama, Takahiro
    Hikita, Hayato
    Tatsumi, Tomohide
    Takehara, Tetsuo
    HEPATOLOGY RESEARCH, 2022, 52 (03) : 298 - 307
  • [2] Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
    Finn, Richard S.
    Qin, Shukui
    Ikeda, Masafumi
    Galle, Peter R.
    Ducreux, Michel
    Kim, Tae-You
    Kudo, Masatoshi
    Breder, Valeriy
    Merle, Philippe
    Kaseb, Ahmed O.
    Li, Daneng
    Verret, Wendy
    Xu, Derek-Zhen
    Hernandez, Sairy
    Liu, Juan
    Huang, Chen
    Mulla, Sohail
    Wang, Yulei
    Lim, Ho Yeong
    Zhu, Andrew X.
    Cheng, Ann-Lii
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (20): : 1894 - 1905
  • [3] Atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma
    Lee, Kyung-Hun
    Lee, Michael S.
    LANCET ONCOLOGY, 2020, 21 (09): : E413 - E413
  • [4] Atezolizumab plus bevacizumab for unresectable or metastatic hepatocellular carcinoma
    D'Alessio, Antonio
    Cammarota, Antonella
    Zanuso, Valentina
    Pressiani, Tiziana
    Personeni, Nicola
    Rimassa, Lorenza
    EXPERT REVIEW OF ANTICANCER THERAPY, 2021, 21 (09) : 927 - 939
  • [5] Atezolizumab plus bevacizumab for advanced, unresectable hepatocellular carcinoma
    Tsilimigras, Diamantis I.
    Moris, Dimitrios
    JOURNAL OF BUON, 2021, 26 (02): : 637 - 638
  • [6] Usefulness of atezolizumab plus bevacizumab as second-line therapy for patients with unresectable hepatocellular carcinoma
    Yamaba, Shinpei
    Imai, Yukinori
    Sugawara, Kayoko
    Uchida, Yoshihito
    Fuchigami, Akira
    Uchiya, Hiroshi
    Nakayama, Nobuaki
    Mochida, Satoshi
    PLOS ONE, 2024, 19 (04):
  • [7] The prediction of early progressive disease in patients with hepatocellular carcinoma receiving atezolizumab plus bevacizumab
    Takeuchi, Yasuto
    Nouso, Kazuhiro
    Fujioka, Shin-ichi
    Kariyama, Kazuya
    Kobashi, Haruhiko
    Uematsu, Shuji
    Moriya, Akio
    Hagihara, Hiroaki
    Takabatake, Hiroyuki
    Nakamura, Shinichiro
    Yabushita, Kazuhisa
    Kikuchi, Tatsuya
    Oyama, Atsushi
    Adachi, Takuya
    Wada, Nozomu
    Onishi, Hideki
    Shiraha, Hidenori
    Takaki, Akinobu
    CANCER MEDICINE, 2023, 12 (17): : 17559 - 17568
  • [8] The Impact of Infections in Patients Treated with Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma
    Esmail, Abdullah
    Xu, Jiaqiong
    Burns, Ethan A.
    Abboud, Karen
    Sheikh, Ali
    Umoru, Godsfavour
    Gee, Kelly
    Wiechmann, Catherine
    Zhang, Yuqi
    Abdelrahim, Maen
    JOURNAL OF CLINICAL MEDICINE, 2024, 13 (17)
  • [9] Risk factors for Early onset of Proteinuria in Patients Receiving Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma.
    Ando, Yuwa
    Kawaoka, Tomokazu
    Kosaka, Masanari
    Shirane, Yuki
    Johira, Yusuke
    Miura, Ryoichi
    Murakami, Serami
    Yano, Shigeki
    Amioka, Kei
    Naruto, Kensuke
    Kosaka, Yumi
    Uchikawa, Shinsuke
    Kodama, Kenichiro
    Fujino, Hatsue
    Nakahara, Takashi
    Ono, Atsushi
    Murakami, Eisuke
    Yamauchi, Masami
    Okamoto, Wataru
    Takahashi, Shoichi
    Imamura, Michio
    Aikata, Hiroshi
    LIVER CANCER, 2023, 12 (03) : 251 - 261
  • [10] OPTIMAL MANAGEMENT OF ATEZOLIZUMAB PLUS BEVACIZUMAB THERAPY FOR PATIENTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA FOCUSING ON THERAPEUTIC MODIFICATIONS
    Tokunaga, Takayuki
    Tateyama, Masakuni
    Kondo, Yasuteru
    Miuma, Satoshi
    Miyase, Shiho
    Tanaka, Kentaro
    Narahara, Satoshi
    Inada, Hiroki
    Kurano, Sotaro
    Yoshimaru, Yoko
    Nagaoka, Katsuya
    Watanabe, Takehisa
    Setoyama, Hiroko
    Tanaka, Yasuhito
    HEPATOLOGY, 2022, 76 : S1351 - S1352
12345